ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids
- PMID: 20043317
- DOI: 10.1002/cyto.b.20509
ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids
Abstract
Background: Enhanced expression of aldehyde dehydrogenase 1 (ALDH1) and phenotypic markers (CD44(+)/CD24(-)) in stem cells from breast tumors has been reported. This study was undertaken to monitor expression of these markers in cells from body cavity fluids of female patients suspected to have a malignancy.
Methods: Cells from peritoneal and pleural fluids of 100 female patients were examined by diagnostic cytology and analyzed by laser flow cytometry for enhanced ALDH1 expression. Cells from 36 body cavity fluids with ALDH1(bright) fluorescence were then analyzed for the expression of CD44 and CD24 markers.
Results: In samples positive for malignancy, ALDH1(bright) cells with both SSC(low) and SSC(high) were seen. In 15 body cavity fluids positive for malignancy, the percentage of ALDH1(bright) cells ranged from 0.26 to 6.34% of the total cells. The percentage of ALDH1(bright) cells with CD44(+)/CD24(-) expression in these samples ranged from 0.02 to 3.66%. ALDH1(bright) cells with CD44(+)/CD24(-) expression were also present in body cavity fluids of patients in whom diagnostic cytology could not detect any malignancy. However, the percentage of ALDH1(bright) and CD44(+)/CD24(-) cells amongst the 21 body cavity fluids with negative cytology was lower than that of samples with malignancy.
Conclusions: Expression of ALDH1(bright) and the CD44(+)/CD24(-) phenotype in body cavity fluids in which diagnostic cytology could not find any malignant cells suggests that this phenotype may not be restricted to the putative breast tumor stem cells. It is possible that only subsets of cells with this phenotype are the putative breast tumor stem cells.
2010 Clinical Cytometry Society.
Similar articles
-
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.Clin Cancer Res. 2009 Jun 15;15(12):4234-41. doi: 10.1158/1078-0432.CCR-08-1479. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509181
-
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.J Clin Pathol. 2011 Nov;64(11):937-46. doi: 10.1136/jcp.2011.090456. Epub 2011 Jun 16. J Clin Pathol. 2011. PMID: 21680574
-
Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.J Clin Pathol. 2013 Mar;66(3):187-91. doi: 10.1136/jclinpath-2012-201169. Epub 2012 Oct 30. J Clin Pathol. 2013. PMID: 23112116
-
Breast cancer stem cells and intrinsic subtypes: controversies rage on.Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. doi: 10.2174/157488809787169110. Curr Stem Cell Res Ther. 2009. PMID: 19149630 Review.
-
A review of the racial heterogeneity of breast cancer stem cells.Gene. 2021 Sep 5;796-797:145805. doi: 10.1016/j.gene.2021.145805. Epub 2021 Jun 29. Gene. 2021. PMID: 34197949 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous